1. Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radical Biology and Medicine. 2012;52(1):59-69.
2. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005-23. doi:10.1002/hep.25762.
3. Takaki A, Kawai D, Yamamoto K. Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH). International journal of molecular sciences. 2014;15(5):7352-79.
4. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221-31. doi:10.1056/NEJMra011775.
5. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038-48. doi:10.1016/j.metabol.2015.12.012.
6. Fang Y-L, Chen H, Wang C-L, Liang L. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From "two hit theory" to "multiple hit model". World journal of gastroenterology. 2018;24(27):2974-83. doi:10.3748/wjg.v24.i27.2974.
7. Mintziori G, Polyzos SA. Emerging and future therapies for nonalcoholic steatohepatitis in adults. Expert Opin Pharmacother. 2016;17(14):1937-46. doi:10.1080/14656566.2016.1225727.
8. Ding R-B, Bao J, Deng C-X. Emerging roles of SIRT1 in fatty liver diseases. International journal of biological sciences. 2017;13(7):852-67. doi:10.7150/ijbs.19370.
9. Menghini R, Casagrande V, Cardellini M, et al. MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. Circulation. 2009;120(15):1524.
10. Moghadam SA, Nematy M, Eghtesadi S, et al. Effects of L-carnitine supplementation on inflammatory factors and malondialdehyde in patients with nonalcoholic steatohepatitis (NASH). Current Topics in Nutraceutical Research. 2015;13:135-41.
11. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nature Protocols. 2008;3(6):1101-8. doi:10.1038/nprot.2008.73.
12. Baranova A, Maltseva D, Tonevitsky A. Adipose may actively delay progression of NAFLD by releasing tumor‐suppressing, anti‐fibrotic miR‐122 into circulation. Obesity reviews. 2019;20(1):108-18.
13. Lin B, Ma Y, Wu S, Liu Y, Liu L, Wu L. Novel serum biomarkers for noninvasive diagnosis and screening of nonalcoholic fatty liver disease-related hepatic fibrosis. Omics: a journal of integrative biology. 2019;23(4):181-9.
14. Musaddaq G, Shahzad N, Ashraf MA, Arshad MI. Circulating liver-specific microRNAs as noninvasive diagnostic biomarkers of hepatic diseases in human. Biomarkers. 2019;24(2):103-9.
15. Ando Y, Yamazaki M, Yamada H, et al. Association of circulating miR-20a, miR-27a, and miR-126 with non-alcoholic fatty liver disease in general population. Scientific reports. 2019;9(1):1-8.
16. Somi MH, Fatahi E, Panahi J, Havasian MR, Judaki A. Data from a randomized and controlled trial of LCarnitine prescription for the treatment for Non- Alcoholic Fatty Liver Disease. Bioinformation. 2014;10(9):575-9. doi:10.6026/97320630010575.
17. Mollica G, Senesi P, Codella R, et al. L-carnitine supplementation attenuates NAFLD progression and cardiac dysfunction in a mouse model fed with methionine and choline-deficient diet. Digestive and Liver Disease. 2020;52(3):314-23. doi:10.1016/j.dld.2019.09.002.
18. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nature reviews Gastroenterology & hepatology. 2010;7(4):195-203.
19. Deng XQ, Chen LL, Li NX. The expression of SIRT1 in nonalcoholic fatty liver disease induced by high‐fat diet in rats. Liver International. 2007;27(5):708-15.
20. Rahman S, Islam R. Mammalian Sirt1: insights on its biological functions. Cell Communication and Signaling. 2011;9(1):11.
21. Yin H, Hu M, Zhang R, Shen Z, Flatow L, You M. MicroRNA-217 promotes ethanol-induced fat accumulation in hepatocytes by down-regulating SIRT1. J Biol Chem. 2012;287(13):9817-26. doi:10.1074/jbc.M111.333534.
22. Gjorgjieva M, Sobolewski C, Dolicka D, de Sousa MC, Foti M. miRNAs and NAFLD: from pathophysiology to therapy. Gut. 2019;68(11):2065-79.
23. Shen Z, Ajmo JM, Rogers CQ, et al. Role of SIRT1 in regulation of LPS- or two ethanol metabolites-induced TNF-alpha production in cultured macrophage cell lines. Am J Physiol Gastrointest Liver Physiol. 2009;296(5):G1047-53. doi:10.1152/ajpgi.00016.2009.
24. Xia H, Ooi LL, Hui KM. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology. 2013;58(2):629-41. doi:10.1002/hep.26369.
25. Sun J, Li ZP, Zhang RQ, Zhang HM. Repression of miR-217 protects against high glucose-induced podocyte injury and insulin resistance by restoring PTEN-mediated autophagy pathway. Biochem Biophys Res Commun. 2017;483(1):318-24. doi:10.1016/j.bbrc.2016.12.145.